Maryland 2026 Regular Session

Maryland House Bill HB808

Introduced
2/4/26  

Caption

Maryland Medical Assistance Program - Step Therapy, Fail-First Protocols, and Prior Authorization - Prescription Drugs to Treat Serious Mental Illness

Impact

If enacted, HB808 would significantly alter the current landscape of prescription drug accessibility for serious mental illnesses under the Maryland Medical Assistance Program. The prohibition of both prior authorization and step therapy would mean that prescribing physicians can directly choose the most appropriate medication without interference. This is anticipated to promote better adherence to treatment regimens, potentially improving health outcomes for individuals suffering from severe mental health conditions. Furthermore, the law will take effect on July 1, 2026, and will remain in force for three years unless amended or repealed by the General Assembly.

Summary

House Bill 808 comprises provisions concerning the Maryland Medical Assistance Program, specifically focusing on the prescription drugs used to treat serious mental illnesses such as bipolar disorder, schizophrenia, major depression, post-traumatic stress disorder, and medication-induced movement disorders. The bill aims to prohibit the application of prior authorization requirements and step therapy protocols under certain circumstances, thereby ensuring more immediate access to prescribed medications for affected individuals. This initiative reflects the legislative intent to reduce barriers that prevent timely and effective mental health treatment for adult enrollees in the program.

Contention

The bill has sparked discussions around potential implications for healthcare providers and the insurance landscape. Supporters assert that eliminating prior authorizations and step therapy practices can lead to more personalized care and quicker access to necessary medications. Conversely, critics might express concerns over the associated costs and the possible risks of unrestricted medication access, emphasizing the need for monitoring to avoid potential over-prescription or misuse. Balancing cost management with the imperative of patient care stands as a critical contention point in the discussions surrounding HB808.

Companion Bills

MD SB490

Crossfiled Maryland Medical Assistance Program - Step Therapy, Fail-First Protocols, and Prior Authorization - Prescription Drugs to Treat Serious Mental Illness

Previously Filed As

MD SB111

Maryland Medical Assistance Program and Health Insurance - Step Therapy, Fail-First Protocols, and Prior Authorization - Prescription to Treat Serious Mental Illness

MD HB382

Maryland Medical Assistance Program and Health Insurance - Step Therapy, Fail-First Protocols, and Prior Authorization - Prescription to Treat Serious Mental Illness

MD SB921

Health Insurance - Step Therapy or Fail-First Protocols - Drugs to Treat Associated Conditions of Advanced Metastatic Cancer

MD HB970

Health Insurance - Insulin - Prohibition on Step Therapy or Fail-First Protocols

MD SB646

Health Insurance - Insulin - Prohibition on Step Therapy or Fail-First Protocols

MD SB974

Maryland Medical Assistance Program and Health Insurance - Nonopioid Drugs for the Treatment of Pain

MD SB876

Maryland Medical Assistance Program - Coverage for the Treatment of Obesity

MD HB776

Maryland Medical Practice Act and Maryland Physician Assistants Act - Revisions

MD SB423

Maryland Medical Practice Act and Maryland Physician Assistants Act - Revisions

MD SB448

Maryland Medical Assistance Program - Self-Directed Mental Health Services - Pilot Program

Similar Bills

No similar bills found.